

QUARTERLY INVESTMENT REVIEW

International Quality ETF

Performance returns (USD)

ANNUALIZED RETURNS (QUARTER-END)	Quarter-End	YTD	1-Year	3-Year	5-Year	10-Year	Since Inception
NAV	2.78	2.78	-	-	-	-	-5.87
MSCI World ex USA	6.20	6.20	-	-	-	-	1.99
Market Price	3.18	3.18	-	-		-	-5.58
MSCI World ex USA	6.20	6.20	-	-		-	1.99

NAV Inception Date: 28-Oct-24

Market Price Inception Date: 28-Oct-24

Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. To obtain performance information to the most recent month-end, visit www.gmo.com. Exchange Traded Funds (ETFs) are bought and sold through exchange trading at market price (not NAV), and are not individually redeemed from the fund. Shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns. The portfolio is actively-managed, is not managed relative to a benchmark and uses the Index for performance comparison purposes only and, where applicable, to compute a performance fee.

MAJOR PERFORMANCE DRIVERS

In a period in which the news flow became a torrent, with a one-man volatility generator in the form of Donald Trump often at the source, global equities had a negative quarter. The divergence in regional returns however was stark; European equities outperformed tech heavier U.S. equities by more than 15%, the widest margin in 35 years. MSCI EAFE returned 6.9% while the S&P 500 fell 4.3%. The International Quality portfolio outperformed our U.S. Quality portfolio (but in a low-quality-favoring environment, trailed EAFE as noted below).

It is hard to separate this European equity renaissance from the new U.S. administration's dealings with traditional U.S. allies (e.g., from playing hardball with NATO over spending contrasting apparent softball with Putin; via attempts to influence politics in third world countries; to tariffs). The aggregate has had something of a galvanizing effect on political leadership. Most notably, Europe's appetite for investment in infrastructure and defense spending was transformed by Germany's decision to unshackle the country from its fiscal debt brake. As a result, European financials and beneficiaries of defense and infrastructure led the market higher. Energy, communications and telecoms also performed well although we do not typically find competitively advantaged business models in these areas. The strategy's best performers were European. Knorr Bremse – the German “brakes for trucks and trains” company with good exposure to potential European infrastructure investment – was the strongest of the group. Safran, Nestle, and Roche were close behind.

Performance for the year of inception is less than a full calendar year. Returns shown for periods greater than one year are on an annualized basis. Holdings subject to change.

Risks: Risks associated with investing in the Fund may include: (1) Market Risk - Equities: the market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares; (2) Management and Operational Risk: the risk that GMO's investment techniques will fail to produce desired results, including annualized returns and annualized volatility; and (3) Non-U.S. Investment Risk: the market prices of many non-U.S. securities (particularly of companies tied economically to emerging countries) fluctuate more than those of U.S. securities. Many non-U.S. markets (particularly emerging markets) are less stable, smaller, less liquid, and less regulated than U.S. markets, and the cost of trading in those markets often is higher than it is in U.S. markets. For a more complete discussion of these and other risks, please consult the Fund's Prospectus.

Performance Returns: Exchange Traded Funds (ETFs) are bought and sold through exchange trading at market price (not NAV), and are not individually redeemed from the fund. Shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns. The GMO ETFs are distributed in the United States by Foreside Fund Services LLC. GMO and Foreside Fund Services LLC are not affiliated.

Total Annual Fund Operating Expenses: 0.60% Expense Ratio is equal to the Fund's Total Annual Operating Expenses set forth in the Fund's most recent prospectus dated October 28, 2024.

QUARTERLY INVESTMENT REVIEW

MAJOR PERFORMANCE DRIVERS CONT.

In our launch white paper^[1] for the International Quality strategy, we highlighted how investors in U.S. equities, especially those with a growth orientation, have been making concentrated bets in the largest tech names. We highlighted how the International Quality strategy could play a role in diversifying this exposure. Even so, we were surprised by the degree to which the Magnificent 7 and the International Quality strategy have offset each other in absolute terms since the strategy's launch. In the period to the end of 2024, the Magnificent 7 rose while the strategy fell. In the first quarter of 2025, the Magnificent 7 tech stocks fell 18% while International Quality stocks rose!

Of course, the strategy's tech holdings, e.g., Taiwan Semiconductors, were not immune from weakness in the Technology sector, but in aggregate the portfolio behaved as one might expect – offering reasonable upside participation during the strongest markets and bringing some resilience during the period of weakness toward quarter end.

In the last couple of days of the quarter and the first week April, markets were materially weak leading into and then coming out of Trump's "Liberation Day." This provided a stern bear market test, and the results were encouraging as the strategy held up several percentage points better than the broader markets.

We tend to aggregate the portfolio into three parts – core, value, and growth – and it was the core group that performed best in the quarter and provided "back bone" during the selloff. The core is spread across Consumer and Healthcare names that tend to be more immune to changes in expectations with regard to the economy.

In this group we would highlight BioMerieux as an example holding. BioMerieux is a French business with a global footprint in medical testing with market leading diagnostic capabilities in bacterial testing (e.g., rapid pathogen identification in sepsis) and infectious disease diagnostics (accurate analysis of samples at scale in hospitals and more recently clinics). Through a combination of in-house research and astute capital allocation, BioMerieux has built a defensible, world class business without reaching for financial leverage. You may not have heard of it, but if you ever have the misfortune to require testing for sepsis, BioMerieux's equipment may just save your life.

Holdings were broadly stable over the quarter. Novo Nordisk and its predecessors have been locked into a battle of innovation around diabetes care with Eli Lilly for a century. Novo's stock has been weak of late as GLP-1 clinical results were relatively disappointing. However, we suspect that leadership will rotate as it has in the past and treated the stock price weakness as an opportunity to add GLP-1 exposure to the strategy at an attractive price point. Timing these purchases is rarely straightforward and Novo is no exception, but we believe that the addition of Novo Nordisk will enhance returns in coming quarters and years.

Portfolio weights as of June 30th, 2025, for the securities mentioned are as follows: bioMerieux SA (1.6%), Knorr-Bremse AG (1.9%), Nestle S.A. (4.4%), Novo Nordisk A/S (3.7%), Roche Holding AG (4.4%), Safran SA (4.3%), Taiwan Semiconductor Manufacturing Co. (4.4%), Eli Lilly (0.0%). Holdings subject to change

[1] International Quality: The Perfect Pairing for Your U.S. Large Cap Portfolio? – available at www.gmo.com

QUARTERLY INVESTMENT REVIEW

PRODUCT OVERVIEW

The GMO International Quality ETF seeks to generate total return by investing primarily in non-U.S. equities the Focused Equity team believes to be of high quality.

The team believes that companies with established track records of historical profitability and strong fundamentals – high quality companies – are able to outgrow the average company over time and are therefore worth a premium price. The GMO International Quality ETF's disciplined approach uses both quantitative and fundamental techniques to assess the relative quality and valuation of non-U.S. companies and aims to exploit a long-term investment horizon while withstanding short-term volatility in an actively managed ETF format.

IMPORTANT INFORMATION

An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the funds prospectus. To obtain a prospectus please visit www.gmo.com. Read the prospectus carefully before investing.

Comparator Index(es): The MSCI World ex-USA Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of global developed markets, excluding the United States. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

The GMO ETFs are distributed in the United States by Foreside Fund Services LLC. GMO and Foreside Fund Services LLC are not affiliated.

ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO*

SINGAPORE

SYDNEY

TOKYO**

*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area

**Representative Office

www.gmo.com